Payment overview · 2025
General Payments
$6,842.62
137 reported records · 28 companies
Healthcare provider profile · identity verified
Abhin Singla, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Addiction Medicine · JOLIET, IL · NPI 1659300796
Verified facts
What the public records show
CMS Open Payments records show Abhin Singla, M.D. received $6,842.62 in general payments during 2025 across 137 reported records.
ABBVIE INC. accounted for 64.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 43 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Linzess, Mounjaro, Nurtec Odt, Ozempic, Qulipta, Rexulti, Ubrelvy, Vraylar, Zenpep, Zubsolv.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Vraylar by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Zenpep by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 206 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Ozempic by this doctor in 2024.
Orexo US, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Zubsolv as an associated drug or biological on 1867 records involving 794 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Zubsolv by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $4,416.27 | 64.5% | 37 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $416.55 | 6.1% | 12 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $261.99 | 3.8% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $194.89 | 2.9% | 10 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $188.43 | 2.8% | 11 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $145.76 | 2.1% | 5 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $143.45 | 2.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $137.65 | 2.0% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $136.98 | 2.0% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $126.49 | 1.9% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $103.40 | 1.5% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $82.60 | 1.2% | 4 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $76.31 | 1.1% | 4 | 2025 |
| Orexo US, Inc. | Unresolved — no canonical attribution shown | $70.71 | 1.0% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $51.44 | 0.8% | 2 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $43.44 | 0.6% | 2 | 2025 |
| Impel Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $39.23 | 0.6% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $27.57 | 0.4% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $25.45 | 0.4% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $20.98 | 0.3% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $19.41 | 0.3% | 1 | 2025 |
| VIVUS LLC | Unresolved — no canonical attribution shown | $17.35 | 0.2% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $17.22 | 0.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $16.90 | 0.2% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $16.27 | 0.2% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $16.13 | 0.2% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $15.37 | 0.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.38 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,750.00 | 2 |
| Food and Beverage | $2,975.99 | 133 |
| Education | $116.63 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $3,935.50 | 12 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $346.51 | 17 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $291.39 | 13 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $240.77 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $194.89 | 10 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $188.43 | 11 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $150.50 | 9 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $145.76 | 5 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $143.45 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $141.86 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $137.65 | 7 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $136.98 | 4 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $134.26 | 8 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $134.26 | 8 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $104.05 | 6 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $93.90 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $84.78 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $84.78 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $82.60 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $82.60 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $82.12 | 4 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $81.88 | 4 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $76.31 | 4 | 2025 |
Source payment records
|
|||||
| Zubsolv Normalized: zubsolv |
Drug | Orexo US, Inc. | $70.71 | 3 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $51.44 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $48.31 | 2 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $43.44 | 2 | 2025 |
Source payment records
|
|||||
| TRUDHESA Normalized: trudhesa |
Drug | Impel Pharmaceuticals LLC | $39.23 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $33.60 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $27.57 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $25.45 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $21.28 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $20.98 | 1 | 2025 |
Source payment records
|
|||||
| ELYXYB - CELECOXIB Normalized: elyxyb celecoxib |
Drug | SCILEX PHARMACEUTICALS INC. | $19.41 | 1 | 2025 |
Source payment records
|
|||||
| PANCREAZE Normalized: pancreaze |
Drug | VIVUS LLC | $17.35 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $17.22 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $17.22 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $16.90 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $16.27 | 1 | 2025 |
Source payment records
|
|||||
| ONZETRA XSAIL Normalized: onzetra xsail |
Drug | Currax Pharmaceuticals LLC | $16.27 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $16.13 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.38 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $8.83 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 66 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 54 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 206 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 127 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Zubsolv zubsolv |
2025 | Zubsolv | 2024 | 52 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
206 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
127 | 25 |
| Orexo US, Inc. Exact reporting entity; no affiliate inference |
2025 | Zubsolv open payments reported associated product |
CMS Open Payments — General Payments 1867 supporting records · 794 recipient NPIs · example record 1190507283 |
Zubsolv · 2024 Exact normalized brand match · 1 Part D row |
52 | 11 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
66 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 397 | 71 |
| Gabapentin | Gabapentin | 248 | 72 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 243 | 43 |
| Mounjaro | Tirzepatide | 206 | 30 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 189 | 29 |
| Losartan Potassium | Losartan Potassium | 187 | 52 |
| Metformin Hcl Er | Metformin Hcl | 186 | 60 |
| Levothyroxine Sodium | Levothyroxine Sodium | 175 | 42 |
| Metformin Hcl | Metformin Hcl | 159 | 46 |
| Duloxetine Hcl | Duloxetine Hcl | 157 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 153 | 46 |
| Alprazolam | Alprazolam | 152 | 29 |
| Omeprazole | Omeprazole | 146 | 44 |
| Clonazepam | Clonazepam | 141 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 139 | 45 |
| Atorvastatin Calcium | Atorvastatin Calcium | 134 | 46 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 128 | 39 |
| Lisinopril | Lisinopril | 127 | 39 |
| Ozempic | Semaglutide | 127 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 122 | 17 |
| Montelukast Sodium | Montelukast Sodium | 117 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 113 | 36 |
| Pregabalin | Pregabalin | 108 | 23 |
| Tramadol Hcl | Tramadol Hcl | 104 | 30 |
| Amlodipine Besylate | Amlodipine Besylate | 102 | 32 |
| Lorazepam | Lorazepam | 93 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 88 | 26 |
| Furosemide | Furosemide | 86 | 28 |
| Baclofen | Baclofen | 81 | 21 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 74 | 11 |
| Famotidine | Famotidine | 74 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 72 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 70 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 70 | 17 |
| Sertraline Hcl | Sertraline Hcl | 69 | 22 |
| Eliquis | Apixaban | 66 | 16 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 62 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 62 | 27 |
| Simvastatin | Simvastatin | 62 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 60 | 21 |
| Carvedilol | Carvedilol | 59 | 18 |
| Ibuprofen | Ibuprofen | 58 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 58 | 15 |
| Trazodone Hcl | Trazodone Hcl | 58 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 56 | 11 |
| Temazepam | Temazepam | 56 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 55 | 13 |
| Farxiga | Dapagliflozin Propanediol | 54 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 52 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 52 | 16 |
| Zubsolv | Buprenorphine Hcl/Naloxone Hcl | 52 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 50 | 17 |
| Bupropion Xl | Bupropion Hcl | 49 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 49 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 48 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 46 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 46 | 15 |
| Celecoxib | Celecoxib | 45 | 11 |
| Potassium Chloride | Potassium Chloride | 45 | 14 |
| Vraylar | Cariprazine Hcl | 45 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 44 | 12 |
| Mirtazapine | Mirtazapine | 42 | 14 |
| Warfarin Sodium | Warfarin Sodium | 42 | suppressed |
| Meloxicam | Meloxicam | 41 | 14 |
| Methocarbamol | Methocarbamol | 41 | suppressed |
| Ondansetron Odt | Ondansetron | 40 | 14 |
| Topiramate | Topiramate | 39 | 13 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 38 | suppressed |
| Trulicity | Dulaglutide | 37 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | 12 |
| Diazepam | Diazepam | 35 | 11 |
| Ezetimibe | Ezetimibe | 35 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 35 | suppressed |
| Azithromycin | Azithromycin | 34 | 24 |
| Aripiprazole | Aripiprazole | 33 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 33 | 11 |
| Lidocaine | Lidocaine | 33 | suppressed |
| Naproxen | Naproxen | 33 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 33 | suppressed |
| Movantik | Naloxegol Oxalate | 32 | suppressed |
| Spironolactone | Spironolactone | 31 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 31 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Modafinil | Modafinil | 30 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 30 | 15 |
| Zenpep | Lipase/Protease/Amylase | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Ubrelvy | Ubrogepant | 28 | suppressed |
| Lovastatin | Lovastatin | 27 | suppressed |
| Metolazone | Metolazone | 27 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 23 |
| Naltrexone Hcl | Naltrexone Hcl | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 21 |
| Nystatin | Nystatin | 24 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Methylprednisolone | Methylprednisolone | 23 | 17 |
| Allopurinol | Allopurinol | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 18 |
| Jardiance | Empagliflozin | 21 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Prednisone | Prednisone | 20 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 13 |
| Cefdinir | Cefdinir | 15 | 14 |
| Finasteride | Finasteride | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 12 |
| Rexulti | Brexpiprazole | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Phenobarbital | Phenobarbital | 14 | suppressed |
| Qulipta | Atogepant | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Acamprosate Calcium | Acamprosate Calcium | 13 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Buprenorphine | Buprenorphine | 12 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 12 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $6,842.62 · 137 records | ABBVIE INC. | AIRSUPRA, AREXVY, ARISTADA, AUSTEDO XR, Auvelity, BREZTRI, BRIXADI, CAPLYTA, CONTRAVE, CREON, ELIQUIS, ELYXYB - CELECOXIB, FANAPT, FARXIGA, FREESTYLE LIBRE 3, INSPIRE, LINZESS, LYBALVI, MOUNJARO, NURTEC ODT, ONZETRA XSAIL, Ozempic, PANCREAZE, QULIPTA, REXULTI, Rybelsus, SHINGRIX, SYNTHROID, Sunosi, Symbravo, TRELEGY ELLIPTA, TRINTELLIX, TRUDHESA, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, WAKIX, XIFAXAN, XYOSTED, ZAVZPRET, ZENPEP, Zubsolv | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error